European Union - English - EMA (European Medicines Agency)

schering-plough europe - posaconazole - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics for systemic use - posaconazole sp is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.posaconazole sp is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who areat high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

Ireland - English - HPRA (Health Products Regulatory Authority)

sol s.p.a. - oxygen - medicinal gas, compressed - 21.75 percent volume/volume - medical gases; oxygen

Australia - English - Department of Health (Therapeutic Goods Administration)

air liquide healthcare pty ltd - oxygen, quantity: 1 l/l - gas, medicinal - excipient ingredients: - .

Australia - English - Department of Health (Therapeutic Goods Administration)

air liquide healthcare pty ltd - oxygen, quantity: 1 l/l - gas, medicinal - excipient ingredients: - for respiratory delivery where there is a requirement for medicinal oxygen to treat or prevent hypoxemia.

Israel - English - Ministry of Health

trupharm marketing 1985 ltd. - medicinal charcoal; rhubarb; sennae folium; sulfur purified - tablets - sennae folium 105 mg; rhubarb 25 mg; sulfur purified 50 mg; medicinal charcoal 180 mg - medicinal charcoal, combinations - medicinal charcoal, combinations - mild laxative, anti-flatulant.

European Union - English - EMA (European Medicines Agency)

air liquide santé international - oxygen - all other therapeutic products - horses; dogs; cats - for oxygen supplementation and as a carrier gas during inhalation anaesthesia.for oxygen supplementation during recovery.